Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia

John Tembo, Nkongho Franklyn Egbe, Kwitaka Maluzu, Kangwa Mulonga, Moses Chilufya, Nathan Kapata, Victor Mukonka, Edgar Simulundu, Alimuddin Zumla, Sombo Fwoloshi, Lloyd Mulenga, Srinivas Reddy Palleria, Thirumalaisamy P. Velavan, Matthew Bates

PII: S1201-9712(22)00216-8
DOI: https://doi.org/10.1016/j.ijid.2022.04.017
Reference: IJID 6125

To appear in: International Journal of Infectious Diseases

Received date: 18 February 2022
Revised date: 7 April 2022
Accepted date: 7 April 2022

Please cite this article as: John Tembo, Nkongho Franklyn Egbe, Kwitaka Maluzu, Kangwa Mulonga, Moses Chilufya, Nathan Kapata, Victor Mukonka, Edgar Simulundu, Alimuddin Zumla, Sombo Fwoloshi, Lloyd Mulenga, Srinivas Reddy Palleria, Thirumalaisamy P. Velavan, Matthew Bates, Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.04.017

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia

John Tembo¹*, Nkongho Franklyn Egbe *², Kwitaka Maluzi*¹, Kangwa Mulonga¹, Moses Chilufya¹, Nathan Kapata³, Victor Mukonka³, Edgar Simulundu⁴, Alimuddin Zumla⁵, Sombo Fwoloshi⁶, Lloyd Mulenga⁶, Srinivas Reddy Palleria⁷, Thirumalaisamy P. Velavan*⁷,⁸, Matthew Bates*¹,²

*Authors contributed equally

Authors affiliations:

¹ HerpeZ, University Teaching Hospital, Lusaka, Zambia
² School of Life & Environmental Sciences, University of Lincoln, Lincoln, United Kingdom
³ Zambia National Public Health Institute, Lusaka, Zambia
⁴ Macha Research Trust, Macha, Southern Province, Zambia
⁵ Centre for Clinical Microbiology, University College London, London, United Kingdom
⁶ Department of Internal Medicine, University Teaching Hospital, Lusaka, Zambia
⁷ Institute for Tropical Medicine, University of Tubingen, Tubingen, Germany
⁸ Vietnamese German Center for Medical Research, Hanoi, Vietnam

Keywords: SARS-CoV-2, COVID-19, diagnostics, serology, real time-PCR, lateral flow test, RDTs, comorbidities
Abstract

Objectives: To conduct a diagnostic validation study of SARS-CoV-2 diagnostic kits.

Methodology: We compared SARS-CoV-2 diagnostic test results from three RT-PCR assays used by the Zambian government between Nov 2020 to Feb 2021 (the Panther Fusion® assay, Da An Gene’s 2019-nCoV RNA kit and Maccura’s PCR Kit) with the Altona RealStar RT-PCR kit which served as the gold standard. We also evaluated results from rapid antigen testing, and whether co-morbidities were linked with increased odds of infection.

Results: We recruited 244 participants, 61% (149/244) were positive by at least one PCR assay. Da An Gene, Maccura and Panther Fusion assays had sensitivities of 0.0% (95%CI 0-41%), 27.1% (95%CI 15-42%) and 76% (95%CI 65-85%) respectively but specificity was low (<85% for all three assays). HIV and TB were not associated with SARS-CoV-2, whereas female sex (OR 0.5 (0.3-0.9), p = 0.026) and Chronic Pulmonary Disease (0.1 (0.0-0.8), p = 0.031), were associated with lower odds of SARS-CoV-2 infection. 84% of 44 samples sequenced were Beta variant.

Conclusions: The RT-PCR assays evaluated did not meet WHO recommended minimum sensitivity of 80%. Local diagnostic validation studies should be embedded within preparedness plans for future outbreaks to improve the public health response.

Introduction

Despite the rapid development and adoption of SARS-CoV-2 diagnostics, SARS-CoV-2 diagnostics have been deployed to resource limited settings without rigorous evaluation. Given the need to ensure tracking of the epidemic and the lack of resources, countries in resource limited settings end up using any available diagnostics. Attempts to establish an effective testing and tracking system have led to indiscriminate use of any
available nucleic acid tests (Twohig et al.), antigen and/or antibody-based tests (Arevalo-Rodriguez et al., 2020, Kobia and Gitaka, 2020), regardless of their diagnostic performance.

In Zambia, SARS-CoV-2 testing has relied on PCR assays and antigen tests that have been donated though the African CDC (Maccara & Da An Gene RT-PCR assays, and Abbott and Roche rapid antigen tests). The Zambian government then procured the Panther PCR assay, with the national testing programme switching between these three assays in accordance with availability. An early outpatient study showed that referral centre testing would be an essential pillar of the diagnostic response to the pandemic in Zambia (Hines et al., 2021).

During Nov 2020-Feb 2021 we implemented an observational clinical diagnostic evaluation study at two COVID-19 referral hospitals in Lusaka, Zambia, to evaluate the performance of these three donated PCR assays, compared with the Altona Diagnostics CE-IVD certified RealStar® SARS-CoV-2 RT-PCR assay, which received FDA EUA on the 22nd April 2020 (Freire-Paspuel et al., 2021) and was the back-bone of the German government’s testing system early in the pandemic. It has been reviewed extensively and been proven to be robust, sensitive and versatile (van Kasteren et al., 2020, Visseaux et al., 2020).

Multiple variants of SARS-CoV-2 have been documented worldwide during this pandemic. Several new SARS-CoV-2 variants recently reported, Alpha, VOC B.1.1.7, Beta, VOC B.1.351, and Gamma VOC B.1.1.28, Delta VOC B.1.617.2. The Alpha, Beta, Gamma, and Delta variants are associated with high transmission, severe illness, and increased mortality (Bal et al., 2021, Challen et al., 2021, Davies et al., 2021, Gaymard et al., 2021, Twohig et al., 2021). More recently the Omicron variant has shown increased potential for immune evasion in various studies (Wang et al., 2022, Zhang et al., 2021). This study took place during ‘Wave 2’
of the pandemic in Zambia, which coincided with the emergence and global spread of the Beta variant of SARS-CoV-2.

The primary objective of this study was to assess inter-test agreement and other important operational characteristics of the diagnostic kits being used in Zambia. Secondary objectives included analysing whether comorbidities (such as tuberculosis or HIV) were associated with infection or poorer outcomes. Whole Genome Sequencing (WGS) was used to determine variants that were circulating within our patient population at the time of the study.

Materials and Methods

Ethics statement
Informed written consent was obtained from all the participants. The study was approved by ERES Converge, Zambia. (Ref No. 2020-JUL-07)

Study population and patient recruitment
The study was conducted at two COVID-19 referral hospitals in Lusaka, Zambia; the University Teaching Hospital (UTH) and Levy Mwanawasa University Teaching Hospital (LMUTH), between Nov 2020 and Feb 2021. All individuals >18 years of age attending accident & emergency with suspected SARS-CoV-2 infection were eligible to be recruited onto the study. After obtaining informed consent they were enrolled in the study and underwent a questionnaire capturing demographics, symptoms, underlying conditions and comorbidity, and recent travel history.
**Specimen collection and Laboratory Analysis**

A nasopharyngeal swab and blood sample was collected from each enrolled participant. One nasopharyngeal swab specimen was collected and placed in 3ml of viral transport media for rapid antigen testing and parallel RT-PCR testing by the government labs using any one of 3 RT-PCR assays used by the National testing program at the time; the Panther Fusion® assay, Da An Gene’s 2019-nCoV RNA kit and Maccura’s PCR Kit and by our research lab using the RealStar SARS-CoV-2 RT-PCR kit (Altona Diagnostics GmbH, Germany).

**Rapid Antigen testing**

Testing was done by the Zambian COVID-19 testing sites using either the Abbott Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostic GmbH, Jena, Germany) or the Roche SD Biosensor SARS-CoV-2 Rapid Antigen Test Nasal Test (Roche Diagnostics, Basel Switzerland) following manufacturer’s guidelines.

**RT-PCR testing**

**Altona SARS-CoV-2 Assay**

RNA extraction for our RT-PCR testing was done using the QIAamp® Viral RNA Mini extraction kit (QIAGEN GmbH, Hilden, Germany) following the manufacturer’s instructions. RT-PCR set up was done with 10 μl of the RNA template in a 30 μl final reaction. The RealStar SARS-CoV-2 RT-PCR kit (altona Diagnostics GmbH, Germany), which targets the E and S genes of SARS-CoV-2, was used for RT-PCR testing on the Rotor-Gene 6000 cycler (QIAGEN GmbH, Hilden, Germany).

For the government laboratories, PCR testing was done using the available kit at the time and according to the manufacturer’s instructions for the specific assay. RNA extraction was
done using QIAamp® Viral RNA Mini extraction kit (QIAGEN GmbH, Hilden, Germany) and the PCR was set up on a Light Cycler 480 or ABI7500 system. The three RT-PCR assays used were Aptima Panther Fusion SARS-CoV-2 assay (Hologic, Inc, San Diego, USA), which targets the ORF1ab gene; the Maccura SARS-CoV-2 assay (Maccura Biotechnology Co., Chengdu, P.R. China), which targets ORF1ab, E & N genes; and the Da An Gene SARS-CoV-2 assay (Daan Gene Co., Guangzhou, Guangdong, P.R. China), which targets the ORF1ab and N genes.

**SARS-CoV-2 sequencing & analysis**

SARS-CoV-2 genomes were sequenced in our laboratory by tiling PCR and Oxford Nanopore NGS sequencing methodologies. Bioinformatic analysis was done using the ARTIC pipeline, as described elsewhere (Manouana et al., 2021) and the lineages were obtained using Pangolin. In brief, tiling PCR was used to amplify 1200bp fragments in two pools, covering the SARS-CoV-2 genome. Amplicons were then purified using AMPure bead purification and barcoded using Rapid barcoding kit (SQK-RBK004) from Oxford Nanopore and purified again before being combined into a full library and loaded onto the MinION for sequencing. Guppy version 3.6.0 was used for basecalling and demultiplexing all runs. The ARTIC Network bioinformatics protocol was used for all genome assembly and variant calling steps, and the lineages were obtained using Pangolin tool (O'Toole et al., 2021). All genomes were aligned with Wuhan-Hu-1 strain (NC_045512.2) using Multiple Alignment Fast Fourier Transform (MAFFT) algorithm (Katoh et al., 2002) and the subsequent phylogenetic tree was constructed with the maximum likelihood method with 1000 bootstrap iterations using the general time-reversible (GTR) model with rate heterogeneity (GTR+G) in the IQ-TREE.
server (Trifinopoulos et al., 2016). The final dataset was displayed using the interactive tree of life (iTOL)v6.

**Anti-SARS-CoV-2 antibody screening**

The presence of SARS-CoV-2 antibodies was determined using the Wantai SARS-CoV-2 total Ab ELISA kit (Wantai Biological, Beijing, China) according to the manufacturer’s instructions. Absorbance readings were obtained using the BioTek EL800 microplate reader (BioTek, Winooski, USA) at 450 nm wavelength. Samples were considered to have anti-SARS-CoV-2 antibodies if the absorbance value was greater than 0.03.

**Data analysis**

Laboratory and clinical data were entered on the EpilInfo version 7.2.4.0 (CDC, USA) and exported as a csv file. It was imported to RStudio version 1.2.5019 (R Core Team, 2019) and cleaned. All statistical analysis was done using packages and functions in RStudio version 1.2.5019 (R Core Team, 2019). Graphics were produced using the ggplot2 package and all confidence intervals (CI) were reported at 95% level (Wickham 2009). A multivariable logistic regression analysis to investigate co-morbidities associated with SARS-CoV-2 infection (either Altona RealStar PCR positive or negative) was done using the R package stats (R Core Team, 2019). Sex and age were added as a fixed effect to the logistic regression and all the recorded co-morbidities (hypertensive, HIV, diabetes, tuberculosis, CPD, asthma, obesity, renal disease, cardiac) and mortality outcome were used as explanatory variables.
Results

Recruitment and Cohort Descriptives

We recruited 244 patients with suspected COVID-19, attending either the University Teaching Hospital (UTH), or Levi Mwanawasa University Teaching Hospital (LMUTH), Lusaka, Zambia. Patients were recruited between the 24th of Nov 2020 and the 5th of Feb 2021, which coincided with the 2nd wave of the COVID-19 Pandemic in Zambia (Figure 1). The COVID-19 isolation ward at LMUTH was established as the primary centre for COVID-19 treatment and care. Capacity was soon reached and so as cases dramatically increased, UTH recruited 134 patients during the first two weeks of January, accounting for 55% of all recruits.

As both hospitals quickly reached capacity, home care was established, with patients triaged, and those with high oxygen saturation sent home to self-care with pulse oximeters.

As such, only half of participants (48%; 115/244) were admitted to hospital (Table 1). The median age of the study cohort was 38 years (IQR 30 - 50yrs) and 53% (130/244) were male (Table 1). The most common symptom was persistent cough, affecting 79% (193/244) of participants, followed by shortness of breath (56%), sore throat (44%) and headache (32%). Loss of taste was relatively uncommon, being reported by just 7.4% (18/244) of participants (Table 1). The median temperature was 36.5°C, with 21% (51/244) recorded as having a fever. 21% (48/244) of participants reported exposure to a known COVID-19 case and 74% (176/237) were recruited within 7 days of symptom onset (Table 1).

Diagnostic assay performance
Among the PCR assays used, the Altona RealStar RT-PCR assay had the highest yield, being positive in 55% (134/244). The yields of the three RT-PCR assays used by the government were highly variable, ranging from 3-55%. In total, 61% (149/244) of participants had a positive PCR result from at least one RT-PCR assay. The rapid antigen test had a lower yield than the two leading PCR assays, being positive in only 33% (54/163) of participants (Table 2).

As the Altona RealStar assay had the highest yield, we used this as a proxy gold standard, against which to compare the other PCR assays and the Ag RDT. Of the three assays used by the Zambian government, the Da An Gene assay performed extremely poorly, failing to detect a single positive case, resulting in a sensitivity of 0% (95%CI 0-41%). The Maccura assay was also extremely insensitive, with a sensitivity of just 27% (95% CI 15-42%). The Panther Fusion assay performed better with a sensitivity of 76% (95% CI 65-85%). But the specificity of both the Panther Fusion and Maccura assays was low, at 80% (95%CI 66-91%) and 84% (95%CI 66-95%) respectively (Table 2).

The Ag RDT test performed poorly, with a sensitivity of just 45% (95%CI 34-56%) and specificity of just 80% (95%CI 69-88%) (Table 2). Performance of the Ag RDT test varied depending on when patients presented themselves for testing post-date of onset of symptoms. The sensitivity and specificity were highest in participants presenting at the hospital within three days from onset of symptoms (53%; 95%CI 34-72% and 84%; 95%CI 66-95% respectively) (Table 3). Test performance also improved when the Ag RDT test was evaluated among 56 participants with a high viral load (defined as an Altona RealStar RT-PCR cycle threshold (Ct) value less than 30); sensitivity was 67%; 95%CI 51-79% and specificity was 100%; 95%CI 54-100% (supplementary table).
The median Ct value of confirmed SARS-CoV-2 cases on the Altona RealStar assay was 27.8 (IQR 21.7 – 32.4). When we compared the mean Ct value of the missed government SARS-CoV-2 cases (false negatives) to the true positives, it was significantly higher (30 vs 24; p<0.01) and 66% of the missed cases had a Ct value greater than 30 (Figure 2).

Seroprevalence

Overall, SARS-CoV-2 antibodies were detected in 37% (91/244) of participants (Table 4). Seroprevalence did not differ significantly, between RT-PCR positives (44% - 59/134) and RT-PCR negatives (29% - 32/110), and also when stratifying by days since onset of symptoms, seroprevalence did not differ significantly by PCR status (Table 4).

SARS-CoV-2 detection & co-morbidity

Hypertension, HIV, Diabetes, Tuberculosis (Tegally et al.) and Chronic Pulmonary Disease (CPD) were the most common co-morbidities, and together accounted for 78.2% (68/87) of participants with co-morbidities. In univariate binary logistic regression analysis, HIV, TB and CPD were all associated with a reduced odds of being SARS-CoV-2 PCR positive with ORs ranging from 0.1-0.3 (Table 5). In a multivariate regression model that included sex and age, along with the highlighted co-morbidity variables, being female (OR 0.5 95%CI 0.3-0.9) and having chronic obstructive pulmonary disease (OR 0.1 95%CI0.0-0.8) were associated with reduced odds of being SARS-CoV-2 positive (Table 5).

SARS-CoV-2 Variants
Only samples that had a Ct value of below 30 and produced a complete consensus sequence on analysis that coverage of over 90% of the genome were submitted to GISAID and are presented here. More than three quarters of the samples sequenced (84.1%; 37/44) were the beta variant (B.1.351 Pangolin lineage), 4 were B.1.306 with 1 sample each being B.1.1.7 and B.1.404. Sixteen of the 44 samples sequenced were missed by all the three government PCR assays; confirming these as true positives. Phylogenetic analysis was undertaken on 44 samples from this study, and 185 Zambian sequences that have been published by other research groups, representing all SARS-CoV-2 sequence data available from samples sequenced in Zambia during the study period. (Figure 3)

Discussion

The main aim of this study was to validate the diagnostics tests used by the Zambian government laboratories for the detection of SARS-CoV-2 infections, against the Altona RealStar RT-PCR assay as gold standard. The overall proportion of RT-PCR positive SARS-CoV-2 cases, positive on any of the RT-PCR assays, was 61.1% (149/244) and the reference assay, -the Altona RealStar SARS-CoV-2 RT-PCR kit was the most sensitive. Of the three government RT-PCR assays used at the time, the Panther Fusion RT-PCR assay was most accurate (sensitivity 76% and specificity 80%) while the Da An Gene was least accurate (sensitivity was 0% and specificity 96.9%). Using the Altona assay as a gold standard, none of the three RT-PCR assays evaluated, met the WHO recommended minimum sensitivity of 80% and specificity of 97% (W.H.O, 2020).
The analytical performance characteristics of these assays provided by the manufacturers does not correlate well with how the assays performed in a real-world clinical setting (Doust et al., 2021), consistent with their rapid development and deployment in the absence of clinical evaluations necessitated by the pandemic. Possible factors which might affect the operational performance in a real-world setting include variations in sample quality, transport and storage, and human factors such as how samples are collected and processed by both clinical and biomedical personnel (Doust et al., 2021, Fung et al., 2020). This study has illustrated the importance of local clinical validation and assay verification, to characterise the performance of a diagnostic test in a specific clinical setting. For novel emerging pathogens, there is no endemic population within which novel diagnostics can be readily evaluated, and so pandemic preparedness planning should include skeleton protocols for the rapid validation of diagnostic assays.

Molecular diagnostic development is traditionally a slow and methodical process. When running two different tests on the same set of samples, there will always be some degree of discordance, and so careful work-up is required to elucidate the reasons for differences and to determine true positives. The SARS-CoV-2 pandemic has challenged this modus operandi, and has showed that the rapid development and deployment of reliable molecular diagnostic assays is a central pillar of the pandemic response. At the time of study design and implementation, there was very little data available on the performance of the diagnostic assays being used, and the results of this study were reported in real time to the Zambian National Public Health Institute, who were able to discontinue use of the Da An Gene assay, which was used in many African countries. At the time of writing only one study had evaluated its use in Benin (Sander et al., 2021). The authors observed good analytical
performance characteristics (using synthetic armoured transcripts) but poor clinical performance which is consistent with the poor clinical performance observed in our study.

In the study herein, the median Ct value of the SARS-CoV-2 cases missed by the government assays was significantly higher than the median Ct value of the true positives (Figure 2), indicating the poor performance might be due to low sensitivity. Conversely, a study from Ecuador reported a higher sensitivity of the Da An Gene assay (75 - 100%) when compared to the CDC 2019-nCoV CDC EUA assay as gold standard (Freire-Paspuel et al., 2021). This alternative gold standard has a higher LoD of 1,000 copies/ml compared to 650 copies/ml for the Altona assay (Freire-Paspuel et al., 2021, Visseaux et al., 2020), and/or there could also be logistical/operational factors which contributed to the discrepancy between the two studies. With the rapid commercializing and scale up of manufacture, there could well have been quality control issues, which affected the performances of certain batches.

SARS-CoV-2 is evolving in both human and animal populations (Lauring and Hodcroft, 2021, Tegally et al., 2021) and when mutations occur in primer or probe sequences, this can impact assay performance (Artesi et al., 2020). Altona Diagnostics have not yet reported any mutations that they think might affect their assay, including for the recent Omicron variant (Diagnostics, 2021). The Altona RealStar assay targets both the E and S genes of the SARS-CoV-2 genome. The Aptima Panther Fusion assay targets ORF1ab and the Maccura assay targets ORF1ab, E & N genes, and the Dan An Gene assay targets the ORF1ab and N genes. We did not observe any probe failures with the Altona RealStar assay but mutations have the capacity to alter diagnostic assay performance, as has been widely documented for certain variants of concern (Valley-Omar et al., 2022, Wollschlager et al., 2021). This re-
enforces the need for assays which detect multiple targets and the broader need for genomic surveillance during pandemics with novel viral pathogens.

In evaluating diagnostics assays, the gold standard or reference test used must be accurate, reliable, efficient, highly sensitive and very robust to ensure the cases are correctly determined as either positives or negatives, and it should be appropriate for the population being tested (Doust et al., 2021). All study participants had one or more COVID-19 symptoms and were within two weeks of symptom onset, a period when the virus should typically be detectable by RT-PCR and antigen screening assays (He et al., 2020, Wolfel et al., 2020). Hence, the cohort of participants used was appropriate for evaluating SARS-CoV-2 diagnostic assays. The Altona Diagnostics RealStar SARS-CoV-2 RT-PCR assay has been extensively reviewed and found to be robust, versatile, and highly sensitive in detecting SARS-CoV-2 infections (van Kasteren et al., 2020, Visseaux et al., 2020). It can detect as low as 625 viral copies/mL compared to 1250 copies/mL LOD for most approved PCR assays (Visseaux et al., 2020). Also, the WHO recommends the use of a nucleic acid amplification test (NAAT) as the gold standard test to evaluate SARS-CoV-2 screening assays (W.H.O, 2020). Hence, the Altona RealStar assay was a credible reference test to use. We sequenced 16 of the samples that were positive only on the Altona assay but negative by the government assays, demonstrating that these were true positives.

The antigen tests evaluated in this study were not reliable in detecting SARS-CoV-2 infections in the general population as both the sensitivity (45%) and specificity (78%) were below the WHO recommended sensitivity of 80% and specificity of 97% (W.H.O, 2020). In other studies the sensitivity of rapid antigen tests varies between 45% and 84.9% (Albert et
There has been much debate about the use of less sensitive lateral flow antigen rapid tests compared to RT-PCR, with some arguing that many RT-PCR positive cases might not be infectious, and that a less sensitive rapid Ag test is a better tool for identifying those who are at the highest risk of infecting others (Mina et al., 2021, Tom and Mina, 2020). The counter argument is that with a test from just one time point, you can’t know whether the viral load might increase, and so RT-PCR is the only effective way to identify a sufficient number of infectious cases, to inform on isolation and stop transmission.

The seroprevalence data from our study indicated that a significant minority of both PCR+ve and PCR-ve cases, had existing antibody to SARS-CoV-2, suggesting prior infection within wave 1, and/or possible cross-reactivity of the ELISA assay used with immunity to other circulating viruses. The overall seroprevalence of 37% among suspected COVID-19 cases, is consistent with a community survey undertaken 6 months prior to the study, which reported seroprevalence of 9% in Lusaka district (Mulenga et al., 2021).

In our study, 78% (68/87) of the participants presented with hypertension, HIV, Diabetes, Tuberculosis (Tegally et al.), and Chronic Pulmonary Disease (CPD) co-morbidities. Suspected cases who had HIV were not at increased risk of SARS-CoV-2 positivity, consistent with previous studies (Charre et al., 2020, Friedman et al., 2021, Inciarte et al., 2020). Our study was under-powered to evaluated whether HIV-infected cases had worse outcomes, but studies elsewhere have suggested HIV is not associated with worse outcomes (Cooper et al., 2020, Nagarakanti et al., 2021). Our observation that chronic obstructive pulmonary
disease (COPD) was associated with a reduced risk of being SARS-CoV-2 positive (OR 0.1 95%CI 0.0-0.8) had a very wide 95%CI and was likely a sample size artefact. A comprehensive review found that COPD was associated with worse outcomes in COVID-19 patients (Leung et al., 2020).

**Limitations of the study**

The findings of our study are limited to symptomatic suspected SARS-CoV-2 cases and cannot be extrapolated to asymptomatic cases, where diagnostic assay performance might vary. We could not reliably match the specific rapid antigen test used by the government labs to the results and they ran out of Ag test kits during the course of the study limiting the statistical power of the antigen test evaluation. The study was implemented during the exponential rise of cases during the second wave of the pandemic and changes in government advice/policy could have affected health seeking behaviour and clinical practice during the study.

**Conclusion**

The RT-PCR assays evaluated did not meet WHO recommended minimum sensitivity of 80%. This highlights the need for all governments to ensure that local plans for diagnostic validation are incorporated into pandemic preparedness planning. Molecular diagnostics have been pivotal in managing the SARS-CoV-2 pandemic and in Zambia and other countries globally, capacity should be maintained/developed to respond to future zoonoses, and could also support much needed surveillance for ongoing endemic infectious disease threats such as antimicrobial resistance. The apparent negative association between female sex and COPD with SARS-CoV-2 had wide confidence limits and should be interpreted with caution.
Conflict of Interest Statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding Source

This work was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme under the PANDORA-ID-NET Consortium (EDCTP Reg/Grant RIA2016E-1609). They had no role in the writing, study design; collection, analysis and interpretation of data and decision to submit the article for publication.

Ethics statement

Informed written consent was obtained from all the participants. The study was approved by ERES Converge, Zambia. (Ref No. 2020-JUL-07) in compliance with the laws of Zambia and the standards of Elsevier journals standards of ethics.

Acknowledgements

JT, KM, KM, MC, NK, ES, AZ, TPV and MB were part of PANDORA-ID-NET Consortium (EDCTP Reg/Grant RIA2016E-1609) funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme which was supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.
REFERENCES

Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernandez-Fuentes MA, et al. Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect 2021;27(3):472 e7-e10.

Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: A systematic review. PLoS One 2020;15(12):e0242958.

Artesi M, Bontems S, Gobbels P, Franckh M, Maes P, Boreux R, et al. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. J Clin Microbiol 2020;58(10).

Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. Euro Surveill 2021;26(3).

Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021;372:n579.
Charre C, Icard V, Pradat P, Brochier C, Lina B, Chidiac C, et al. Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users. AIDS 2020;34(12):1765-70.

Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med 2020;21(9):567-77.

Davies NG, Jarvis CI, Group CC-W, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021;593(7858):270-4.

Diagnostics A. RealStar® and AltoStar® SARS-CoV-2 RT-PCR kits detect E gene and S gene variants of SARS-CoV-2 sequences. 2021.

Douš J, Bell KJL, Leeflang MMG, Dinnes J, Lord SJ, Mallett S, et al. Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. BMJ 2021;372:n568.

Freire-Paspuel B, Bruno A, Orlando A, Garcia-Bereguiain MA. Analytical and Clinical Evaluation of Two RT-qPCR SARS-CoV-2 Diagnostic Tests with Emergency Use Authorization in Ecuador. Am J Trop Med Hyg 2021.

Friedman EE, Devlin SA, McNulty MC, Ridgway JP. SARS-CoV-2 percent positivity and risk factors among people with HIV at an urban academic medical center. PLoS One 2021;16(7):e0254994.
Fung B, Gopez A, Servellita V, Arevalo S, Ho C, Deucher A, et al. Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays. J Clin Microbiol 2020;58(9).

Gaymard A, Bosetti P, Feri A, Destrás G, Enouf V, Andronico A, et al. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. Euro Surveill 2021;26(9).

He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26(5):672-5.

Hines JZ, Fwoloshi S, Kampamba D, Barradas DT, Banda D, Zulu JE, et al. SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020. Emerg Infect Dis 2021;27(8):2166-8.

Igloi Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, et al. Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. Emerg Infect Dis 2021;27(5):1323-9.

Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS 2020;34(12):1775-80.

Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 2002;30(14):3059-66.
Kobia F, Gitaka J. COVID-19: Are Africa's diagnostic challenges blunting response effectiveness? AAS Open Res 2020;3:4.

Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso AM, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. J Clin Microbiol 2020;58(8).

Lauing AS, Hodcroft EB. Genetic Variants of SARS-CoV-2-What Do They Mean? JAMA 2021;325(6):529-31.

Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J 2020;56(2).

Linares M, Perez-Tanoira R, Carrero A, Romanyk J, Perez-Garcia F, Gomez-Herruz P, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. J Clin Virol 2020;133:104659.

Mina MJ, Peto TE, Garcia-Finana M, Semple MG, Buchan IE. Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. Lancet 2021;397(10283):1425-7.

Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Health 2021;9(6):e773-e81.

Nagarakanti SR, Okoh AK, Grinberg S, Bishburg E. Clinical outcomes of patients with COVID-19 and HIV coinfection. J Med Virol 2021;93(3):1687-93.
O’Toole A, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol 2021;7(2):veab064.

Osterman A, Baldauf HM, Eletreby M, Wettengel JM, Afridi SQ, Fuchs T, et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Med Microbiol Immunol 2021;210(1):65-72.

Sander AL, Yadouleton A, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in Benin, Western Africa. mSphere 2021;6(1).

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021;592(7854):438-43.

Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clin Infect Dis 2020;71(16):2252-4.

Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res 2016;44(W1):W232-5.

Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2021.

Valley-Omar Z, Marais G, Iranzadeh A, Naidoo M, Korsman S, Maponga T, et al. Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of
the Delta SARS-CoV-2 variant using routine diagnostic tests. J Virol Methods 2022;302:114471.

van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol 2020;128:104412.

Visseaux B, Le Hingrat Q, Collin G, Ferre V, Storto A, Ichou H, et al. Evaluation of the RealStar(R) SARS-CoV-2 RT-PCR kit RUO performances and limit of detection. J Clin Virol 2020;129:104520.

W.H.O. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic 2020.

Wang Y, Zhang L, Li Q, Liang Z, Li T, Liu S, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect 2022;11(1):1-5.

Wickham H. ggplot2: Elegant graphics for data analysis. 2nd edition ed: Springer, 2009.

Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581(7809):465-9.

Wollschlager P, Todt D, Gerlitz N, Pfaender S, Bollinger T, Sing A, et al. SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay. Clin Microbiol Infect 2021;27(9):1353 e1- e5.

Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther 2021;6(1):430.
Figure 1: Timeline showing number of patients recruited each week from each of the participating hospitals, along with the overall trajectory of the pandemic (cases/day) within Zambia nationally during the same period. UTH = University Teaching Hospital, LMUTH = Levi Mwanawasa University Teaching Hospital.
Figure 2

CT values (Altona) by government PCR result

Median = 32 (IQR: 27 - 34)  
Median = 24 (IQR: 20 - 30)

Figure 2: A Plot of the Ct value (Altona assay) of confirmed SARS-CoV-2 cases showing the difference between false negatives (cases missed by the government RT-PCR assays) and true positives (participants positive on both the government RT-PCR assays and Altona RealStar assay).
Figure 3: Phylogenetic Tree Maximum likelihood phylogenetic tree of currently available SARS-CoV-2 genomes from the Republic of Zambia collected during the study period Nov 2020 to Feb 2021. Coloured in accordance with SARS-CoV-2 variant type. Coloured id labels on nodes indicate samples sequenced by laboratory during the course of the study. All the full-length genomes retrieved from the GISAID (global database for influenza gene sequences) labelled as country of origin, GISAID ID. Branch lengths are drawn according to the number of nucleotide substitutions per site.
Table 1: Characteristics of 244 participants attending hospital with suspected COVID-19.

| Characteristic                          | Comorbidity n= 89 | No comorbidity n= 155 | All Participants n= 244 (%) |
|----------------------------------------|-------------------|------------------------|-----------------------------|
| Median Age in Years (IQR)              | 46 (36 - 61)      | 35 (28 – 43)          | 38 (30 - 50)                |
| Sex (male)                             | 46                | 83                     | 129 (53%)                   |
| Admitted                               | 62                | 53                     | 115 (47)                    |
| **Symptoms**                           |                   |                        |                             |
| Cough                                  | 72                | 121                    | 193 (79)                    |
| Shortness of Breath                    | 65                | 72                     | 137 (56)                    |
| Sore Throat                            | 37                | 71                     | 108 (44)                    |
| Headache                               | 20                | 57                     | 77 (32)                     |
| Chest Pain                             | 19                | 30                     | 49 (20)                     |
| Diarrhoea                              | 13                | 17                     | 30 (12)                     |
| Nausea                                 | 15                | 15                     | 29 (12)                     |
| Runny Nose                             | 11                | 18                     | 29 (12)                     |
| Loss of Taste                          | 5                 | 13                     | 18 (7)                      |
| Median Temperature °C (IQR)            | 36.5 (36 - 37)    | 36.5 (36 - 37)        | 36.5 (36 - 37)              |
| Days since onset of symptoms*          |                   |                        |                             |
| 0-3 Days                               | 27                | 62                     | 89 (38)                     |
| 4-7 Days                               | 30                | 57                     | 87 (37)                     |
|                | Altona RealStar | Diagnostic Performance characteristics |
|----------------|---------------|---------------------------------------|
|                | Negative | Positive | Sensitivity | Specificity | PPV $^a$ | NPV $^a$ |
| Da An Gene     | Negative  | 31        | 7           | 0.0% (0-41%) | 96.9% (84-100%) | 0.0% | 81.6% (43-46%) |
|                | Positive  | 1         | 0           |             |           |           |             |
| Maccura        | Negative  | 26        | 35          | 27.1% (15-42%) | 83.9% (66-95%) | 67.3% (45-84%) | 48.4% (43-54%) |
|                | Positive  | 5         | 13          |             |           |           |             |
| Panther Fusion*| Negative  | 37        | 19          | 76% (65-85%) | 80.4% (66-91%) | 82.7% (72-90%) | 73.2% (64-81%) |
|                | Positive  | 9         | 60          |             |           |           |             |
| Ag RDT         | Negative  | 59        | 48          | 44.8% (34-56%) | 79.7% (69-88%) | 73.1% (62-82%) | 54% (49-60%) |
|                | Positive  | 15        | 39          |             |           |           |             |
| All gov't assays $^a$ | Negative  | 87        | 44          | 67% (56-75%) | 79.1% (70-86%) | 80% (71-87%) | 66.4% (58-74%) |
|                | Positive  | 23        | 90          |             |           |           |             |

$^a$ Based on a prevalence of 55.1% $^b$ Positive case defined as positive on any of the RT-PCR assays used by the government or rapid antigen test. A positive result either on the rapid Ag or RT-PCR assays was notified as a confirmed COVID-19 case by the government.
### Table 3 – Sensitivity and Specificity of the Rapid Antigen test stratified by the number of days since symptoms onset.

| Days since onset of symptoms** | Ag RDT* | Negative | Positive | Sensitivity | Specificity |
|-------------------------------|---------|----------|----------|-------------|-------------|
| **0-3 Days**                  | Negative | 26       | 14       | **53.3% (34-72%)** | **83.9% (66-95%)** |
|                               | Positive | 5        | 16       |             |             |
| **4-7 Days**                  | Negative | 17       | 20       | **42.8% (26-61%)** | **68% (47-85%)** |
|                               | Positive | 8        | 15       |             |             |
| **>= 8 Days**                 | Negative | 13       | 14       | **36.4% (17-59%)** | **92.9% (66-99.8%)** |
|                               | Positive | 1        | 8        |             |             |
| **All**                       | Negative | 60       | 48       | **44.8% (34-56%)** | **79.7% (69-88%)** |
|                               | Positive | 15       | 39       |             |             |

* Rapid antigen test not done for 82 participants. ** Number of days since the onset of symptoms unknown for 7 participants.
**Table 4** – Seroprevalence by Wantai ELISA stratified by Altona RealStar RT-PCR result and days since onset of symptoms

| Days since onset of symptoms** | Altona RealStar | Wantai ELISA seropositive |
|-------------------------------|----------------|---------------------------|
| **0-3 Days**                  |                |                           |
| Negative                      | 27% (12/45)    |                           |
| Positive                      | 36% (16/44)    |                           |
| **4-7 Days**                  |                |                           |
| Negative                      | 29% (12/41)    |                           |
| Positive                      | 39% (18/46)    |                           |
| **>= 8 Days**                 |                |                           |
| Negative                      | 32% (6/19)     |                           |
| Positive                      | 60% (25/42)    |                           |
| **All participants**          |                |                           |
| Negative                      | 29% (32/110)   |                           |
| Positive                      | 44% (59/134)   |                           |

*Number of days since the onset of symptoms unknown for 7 participants.*
**Table 5** – Binary logistic regression analysis of various co-morbidities as risk factors for being SARS-CoV-2 PCR positive.

|                  | Altona RealStar | Univariate | Multivariate |
|------------------|-----------------|------------|--------------|
|                  | Negative        | Positive   | OR (95%CI)   | p      | OR (95%CI)   | p      |
| **Median Age (IQR)** | 37 (29-48)      | 40 (30-52) | 1.0 (1.0-1.0)| 0.207  | 1.0 (1.0-1.0)| 0.211  |
| **Sex (female)**  | 58/109          | 56/134     | 0.6 (0.4-1.1)| 0.077  | 0.5 (0.3-0.9)| 0.026  |
| **Any Comorbidity** | 46/109          | 41/134     | 0.6 (0.36-1.0)| 0.061  |          |
| **Hypertensive**  | 17/109          | 33/134     | 1.8 (0.9-3.4)| 0.086  |          |
| **HIV**           | 19/109          | 8/134      | 0.3 (0.1-0.7)| 0.007  | 0.4 (0.2-1.1)| 0.086  |
| **Diabetes**      | 7/109           | 8/134      | 0.9 (0.3-2.6)| 0.884  |          |
| **Tuberculosis**  | 10/109          | 3/134      | 2.2 (0.2-18.3)| 0.027  | 0.4 (0.1-1.6)| 0.189  |
| **CPD**           | 8/109           | 1/134      | 0.1 (0.0-0.8)| 0.028  | 0.1 (0.0-0.8)| 0.031  |
| **Asthma**        | 3/109           | 2/134      | 1.5 (0.5-3.3)| 0.498  |          |
| **Obesity**       | 1/109           | 3/134      | 2.2 (0.3-24)| 0.436  |          |
| **Renal Disease** | 2/109           | 1/134      | 0.7 (0.0-4.5)| 0.460  |          |
| **Cardiac**       | 1/109           | 2/134      | 1.5 (0.1-18.3)| 0.689  |          |
| **Outcome - Died** | 2/80            | 1/85       | 1.2 (0.5-5.2)| 0.534  |          |

*outcome data was only available for patients who were admitted (n=165)*